COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients: A Prospective Observational Registry

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY

This is a subject registry study of patients who undergo cryoablation for their breast cancer after being determined not to be surgical candidates. Data collected as part of this registry will be used to assess the safety of percutaneous ultrasound-guided cryoablation in this population as well as provide long-term follow-up of subjects who received cryoablation.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

∙ Eligibility Criteria:

• Diagnosis of breast cancer.

• Mass must be visible on ultrasound and \> 5 mm from skin.

• Not undergoing surgery, because:

‣ Patient has a medical condition that would not allow sedation or general anesthesia

⁃ Surgery is not clinically indicated due to unresectable and/or metastatic disease

⁃ Surgery is not clinically indicated for another reason

⁃ Patient declines surgery

• At least 18 years old.

• Able to understand and willing to sign an IRB-approved written informed consent document.

Locations
United States
Missouri
Washington University School of Medicine
RECRUITING
St Louis
Contact Information
Primary
Heather Garrett, M.D.
hvgarrett@wustl.edu
314-454-5206
Time Frame
Start Date: 2023-07-26
Estimated Completion Date: 2031-07-31
Participants
Target number of participants: 100
Treatments
Cryoablation
Following pre-procedural imaging evaluation, patients will receive ultrasound-guided percutaneous cryoablation as part of their routine treatment of their breast cancer. Follow up imaging (if tolerated) will be performed at 6 months and 12 months and annually thereafter for until 3 years post-procedure. Data will be collected on patient demographics, disease characteristics, treatment, treatment complications, follow-up imaging, response (for 3 years post-procedure), and quality of life.
Related Therapeutic Areas
Sponsors
Leads: Washington University School of Medicine

This content was sourced from clinicaltrials.gov